PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer

Gelijkaardige items

• PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
  door: Concha-Benavente, Fernando, et al.
  Gepubliceerd in: (2018)
• Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
  door: Trivedi, Sumita, et al.
  Gepubliceerd in: (2015)
• CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients
  door: Srivastava, Raghvendra M., et al.
  Gepubliceerd in: (2016)
• IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
  door: Concha-Benavente, Fernando, et al.
  Gepubliceerd in: (2014)
• Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model
  door: Srivastava, Raghvendra M, et al.
  Gepubliceerd in: (2015)